版本:
中国

BRIEF-Akebia and Vifor Pharma announce license agreement to provide vadadustat to Fresenius Medical Care in the U.S. upon FDA approval

May 15 Akebia Therapeutics Inc

* Akebia and Vifor Pharma announce exclusive license agreement to provide vadadustat to Fresenius Medical Care in the U.S. upon FDA approval

* Vifor Pharma will also make a $50 million equity investment in akebia at $14 per share

* Vifor to exclusively distribute vadadustat to Fresenius Medical Care North America for use solely within dialysis facilities in U.S. Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐